ASO Author Reflections: PSMA PET in the Prostate Cancer Primary Staging Scenario—A Reliable Method with a Remarkable Decision-Making Impact
Abstract Prostate cancer (PCa) is the second most common malignant tumor in men in Brazil and worldwide. Although positron emission tomography (PET) prostate-specific membrane antigen (PSMA) has been used for over 10 years and several studies have been published regarding its superior performance in PCa primary staging and other scenarios, the management decision is often still based on conventional imaging information. A retrospective analysis was performed in 35 patients with PCa in the primary staging scenario with conventional exams as well as with PET PSMA. The findings of our study showed changes on the staging classification and significant impact on the therapeutic choice. PET PSMA is a dependable imaging exam and has already proved its worth and superiority when compared with conventional methods to evaluate PCa patients in primary staging and biochemical relapse, in addition to other potential roles. Prospective studies are needed to assess the outcome of patients whose management was guided by PSMA..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
---|---|
Enthalten in: |
Annals of surgical oncology - 30(2023), 7 vom: 03. Apr., Seite 4550-4551 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
da Silva, Anna Carolina Borges [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Anmerkungen: |
© Society of Surgical Oncology 2023 |
---|
doi: |
10.1245/s10434-023-13426-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2143760051 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2143760051 | ||
003 | DE-627 | ||
005 | 20240118091618.0 | ||
007 | tu | ||
008 | 240118s2023 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1245/s10434-023-13426-2 |2 doi | |
035 | |a (DE-627)OLC2143760051 | ||
035 | |a (DE-He213)s10434-023-13426-2-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
100 | 1 | |a da Silva, Anna Carolina Borges |e verfasserin |0 (orcid)0000-0003-4999-3501 |4 aut | |
245 | 1 | 0 | |a ASO Author Reflections: PSMA PET in the Prostate Cancer Primary Staging Scenario—A Reliable Method with a Remarkable Decision-Making Impact |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © Society of Surgical Oncology 2023 | ||
520 | |a Abstract Prostate cancer (PCa) is the second most common malignant tumor in men in Brazil and worldwide. Although positron emission tomography (PET) prostate-specific membrane antigen (PSMA) has been used for over 10 years and several studies have been published regarding its superior performance in PCa primary staging and other scenarios, the management decision is often still based on conventional imaging information. A retrospective analysis was performed in 35 patients with PCa in the primary staging scenario with conventional exams as well as with PET PSMA. The findings of our study showed changes on the staging classification and significant impact on the therapeutic choice. PET PSMA is a dependable imaging exam and has already proved its worth and superiority when compared with conventional methods to evaluate PCa patients in primary staging and biochemical relapse, in addition to other potential roles. Prospective studies are needed to assess the outcome of patients whose management was guided by PSMA. | ||
700 | 1 | |a de Toledo, Luís Gustavo Morato |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Annals of surgical oncology |d Springer International Publishing, 1994 |g 30(2023), 7 vom: 03. Apr., Seite 4550-4551 |w (DE-627)182355047 |w (DE-600)1200469-8 |w (DE-576)046647635 |x 1068-9265 |7 nnns |
773 | 1 | 8 | |g volume:30 |g year:2023 |g number:7 |g day:03 |g month:04 |g pages:4550-4551 |
856 | 4 | 1 | |u https://doi.org/10.1245/s10434-023-13426-2 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a GBV_ILN_2018 | ||
951 | |a AR | ||
952 | |d 30 |j 2023 |e 7 |b 03 |c 04 |h 4550-4551 |